Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by palinc2000on Apr 13, 2022 5:07pm
135 Views
Post# 34601878

So much distrust

So much distrustAs my favorite poster once said '' quit whining and sell and move on"
I think he should follow his own advice


The problem here  for some is the is lack of experience in how clinical trials are conducted....I have learned the hard way to only bet money I dont need on clinical trials be they Phase 1  .phase 2 or even Phase 3,...Cancers are the hardest to treat ilnesses especially for advanced patients....Miracle cures are not run of the mill ....Those who have fantasized about fantastic results in Phase 1a have set themselves up for disappointment....Those who thought the purchase of Katana 3 years ago was akin to buying a Lottery Ticket (which it was) are pleased with where we stand now in Oncology...

I am disapointed with the F8 formulation being on hold 9not the company s fault) and the corresponding hold on Nash........I am still a believer inTesamorelin .....Paul did not elaborate today on the reasons that Egrifta is gaining traction but I think HIV doctors are starting to prescribe Egrifta to their Lipo patients as a prevention for Nash   ALL legal and according to the multitude of studies posted by Scarlett prescribing Tesamorelin is a win win situation for Lipo patients

I read the transcripts of the CC and I still think that financing is a big challenge ......time will tell
<< Previous
Bullboard Posts
Next >>